MetaCap

Merck (MRK) vs Pfizer (PFE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Merck (MRK) has outperformed Pfizer (PFE) over the past year, gaining 36.8% versus a gain of 9.4%. Over five years, MRK leads with a +68.9% price change compared with -49.3% for PFE. Merck is the larger company by market cap ($329.65 billion vs $156.18 billion), about 2.1 times the size.

On valuation, Pfizer trades at a lower forward P/E (9.3x vs 14.9x for Merck). Pfizer offers the higher dividend yield (7.85% vs 2.51%). Merck converts more of its revenue into profit, with a net margin of 28.1% versus 12.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MRK+36.78%PFE+9.42%
+63%+27%-9%
Nov 21, 20251 yearNov 20, 2026
MRK+65.70%PFE-46.06%
+96%+16%-64%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MRK versus PFE key metrics
MetricMRKPFE
Share price$133.72$27.40
Market cap$329.65B$156.18B
1-day change+0.69%-0.51%
YTD return+27.04%+10.04%
1-year return+36.78%+9.42%
5-year return+68.92%-49.26%
P/E ratio (TTM)135.0739.14
Forward P/E14.929.28
EPS (TTM)$0.99$0.70
Dividend yield2.51%7.85%
Annual dividend$3.36$2.15
Revenue (latest FY)$65.01B$62.58B
Revenue growth (YoY)+1.31%-1.65%
Net income (latest FY)$18.25B$7.77B
Gross margin74.80%74.33%
Net margin28.08%12.42%
52-week high$156.92$31.44
52-week low$96.06$23.62
Distance from 52-week high-14.78%-12.85%
Analyst consensusbuybuy
Avg. price target upside+20.80%+10.29%
Average volume9.81M33.52M
Shares outstanding2.47B5.70B
Employees73,00075,000
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Merck is about 2.1 times larger than Pfizer by market value ($329.65B vs $156.18B).
  • MRK has outperformed PFE by 27.4 percentage points over the past year.
  • Merck trades at a higher earnings multiple (135.1x vs 39.1x trailing P/E).
  • Pfizer offers a meaningfully higher dividend yield (7.85% vs 2.51%).
  • Merck is more profitable, keeping 28.1 cents of every revenue dollar as net income versus 12.4 cents for Pfizer.

About Merck

MRK stock →

Merck & Co., Inc. operates as a healthcare company worldwide.

Health Care · Biotechnology: Pharmaceutical Preparations · 73,000 employees

About Pfizer

PFE stock →

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 75,000 employees

MRK vs PFE FAQ

Which is bigger, Merck or Pfizer?

Merck (MRK) is larger, with a market capitalization of $329.65B compared with $156.18B for Pfizer (PFE).

Which stock has performed better over the past year, MRK or PFE?

MRK returned +36.78% over the past 12 months, compared with +9.42% for PFE (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, MRK or PFE?

PFE has the lower trailing P/E at 39.1, versus 135.1 for MRK. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Merck or Pfizer?

Pfizer has the higher yield at 7.85%, compared with 2.51% for Merck.

Are Merck and Pfizer in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons